BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Public ClinicalTrials.gov record NCT00326963. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label Study Evaluating the Safety and Efficacy of a New Protease Inhibitor (Darunavir) With Fuzeon® (Enfuvirtide) Plus Background Antiretroviral Regimen in HIV-1 Infected, Triple-class Treatment-experienced Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This single arm study will evaluate the efficacy, safety and tolerability of a new investigational protease inhibitor (PI) plus background antiretrovirals plus Fuzeon (90mg sc bid) in HIV-1 infected, triple-class treatment-experienced, Fuzeon-naive adults. The new investigational PI will be administered according to the procedures of the early access program in which the patient is enrolled. The anticipated time on study treatment is 3-12 months, and the target sample size is approximately 120 individuals.
Study identification
- NCT ID
- NCT00326963
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 142 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2006 (Type not available)
- Primary completion
- Apr 2007 (Actual)
- Completion
- May 2007 (Actual)
- Last update posted
- Aug 16, 2016
2006 – 2007
United States locations
- U.S. sites
- 32
- U.S. states
- 15
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | 85006 | — |
| Not listed | Bakersfield | California | 93301 | — |
| Not listed | Beverly Hills | California | 90210 | — |
| Not listed | Los Angeles | California | 90027 | — |
| Not listed | Los Angeles | California | 90028 | — |
| Not listed | Los Angeles | California | 90036 | — |
| Not listed | San Francisco | California | 94114 | — |
| Not listed | Stanford | California | 94305 | — |
| Not listed | Tarzana | California | 91356 | — |
| Not listed | Norwalk | Connecticut | 06851 | — |
| Not listed | Washington D.C. | District of Columbia | 20009 | — |
| Not listed | Fort Lauderdale | Florida | 33334 | — |
| Not listed | Orlando | Florida | 32803 | — |
| Not listed | Port Saint Lucie | Florida | 34952 | — |
| Not listed | Decatur | Georgia | 30033 | — |
| Not listed | Macon | Georgia | 31201 | — |
| Not listed | Baltimore | Maryland | 21201 | — |
| Not listed | St Louis | Missouri | 63139 | — |
| Not listed | Newark | New Jersey | 07102 | — |
| Not listed | Somers Point | New Jersey | 08244 | — |
| Not listed | Albany | New York | 12208 | — |
| Not listed | New York | New York | 10003 | — |
| Not listed | New York | New York | 10032 | — |
| Not listed | Huntersville | North Carolina | 28078 | — |
| Not listed | Portland | Oregon | 97209-2534 | — |
| Not listed | Philadelphia | Pennsylvania | 19107 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | Fort Worth | Texas | 76104 | — |
| Not listed | Houston | Texas | 77004 | — |
| Not listed | Houston | Texas | 77098 | — |
| Not listed | Annandale | Virginia | 22003 | — |
| Not listed | Hampton | Virginia | 23666 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00326963, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2016 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00326963 live on ClinicalTrials.gov.